Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
This article was originally published in The Pink Sheet Daily
Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.
You may also be interested in...
Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.
Valeant jumps back into M&A, acquiring Salix after wholesale inventory issues discouraged other potential buyers. Merck more or less options a pipeline with its five-year R&D collaboration with NGM Pharma.
Amid a dearth of private-sector deals, we review some of this year’s break-ups, take a closer look at the Leukemia & Lymphoma Society’s deal-making strategy and highlight two deals from the U.K.’s Cancer Research Technology, as well as a licensing pact between Adimab and Alector.